Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease
Advanced Science · 2026
DOI: 10.1002/advs.76394 ↗At a glance
Journal article in Advanced Science, 2026. Written by Qing Yan and 29 co-authors. Institution: Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, In…. Major MEDLINE topics: Parkinson Disease, Dopaminergic Neurons, Induced Pluripotent Stem Cells, Cell- and Tissue-Based Therapy. Cited 1 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Key R&D Program of China, National Natural Science Foundation of China, Guangdong Special Support Program for Health and Medical Talents.
Abstract (original language)
Human induced pluripotent stem cell (iPSC)‐derived dopaminergic progenitors offer a promising strategy for cell replacement in Parkinson's disease (PD), yet their long‐term efficacy and safety in primates remain underexplored. Here, we generated isogenic iPSC lines from a PD patient carrying compound LRRK2 mutations (R50H and M2397T) and used CRISPR/Cas9 and prime editing to correct these variants. Both mutant and gene‐corrected lines were differentiated into midbrain dopaminergic progenitors (DA‐NPCs), characterized in vitro, and transplanted bilaterally into the striatum of MPTP‐lesioned cynomolgus monkeys. Over 18 months, grafted cells survived, expressed TH and GIRK2, and exhibited mature electrophysiological properties. [ 1 8 F] DOPA PET imaging revealed restored dopamine synthesis in both grafting groups, with no statistically significant differences observed between mutant and gene‐corrected groups. Behavioral assessments showed sustained motor improvements and enhanced exploratory behavior. No tumor formation or adverse astrocytic response was observed, and systemic safety markers remained normal. These findings demonstrate that both mutant and corrected DA‐NPCs integrate and function in the primate brain. Our results support the feasibility of personalized regenerative therapies for genetic PD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, Institute of Zoology, Guangdong Academy of Sciences, Guangzhou, Guangdon…
- Zhuzhou Central Hospital, Zhuzhou, Hunan, China.
- Guangzhou Regenverse Therapeutics Co., Ltd, Guangzhou, China.
- Chengdu Wenjiang District People's Hospital, Chengdu, China.
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
- Laboratory of Genomic and Precision Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
ORCID profiles: Jianhuan Chen
Funding
- National Key R&D Program of China
- National Natural Science Foundation of China
- Guangdong Special Support Program for Health and Medical Talents
- GDAS' Project of Science and Technology Development
- Key Science and Technology Project of Guangdong Province, China
Cite
APA
Yan, Q., Xu, C., Gao, J., Wang, P., Wu, Q., Jin, Y., Lu, B., Li, M., Shao, M., Li, B., Su, Z., Zhang, Y., Chen, J., An, H., Huang, M., Zhuang, X., Shen, Y., Wang, F., Xu, N., …, & Rao, J. (2026). Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease. Advanced Science. https://doi.org/10.1002/advs.76394
Vancouver
Yan Q, Xu C, Gao J, Wang P, Wu Q, Jin Y, et al. Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease. Advanced Science. 2026. doi:10.1002/advs.76394
BibTeX
@article{Yan2026,
author = {Yan, Qing and Xu, Chongchong and Gao, Jiangmei and Wang, Pu and Wu, Qingling and Jin, Ying and Lu, Binyan and Li, Mu and Shao, Mingting and Li, Bihai and Su, Zhenghui and Zhang, Yijng and Chen, Jianhuan and An, Haojie and Huang, Mengyao and Zhuang, Xiaoji and Shen, Yuhui and Wang, Fenglin and Xu, Nana and Liu, Yiyan and Tang, Lei and Zhong, Xiuling and Zhong, Minyan and Chen, Jiecong and Wang, Zhenhuang and Luo, Xingrong and Liu, Sheng and Liu, RuiFeng and Zhang, Ling and Rao, Junhua},
title = {Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76394}
}
EUVIMED